More Information

By Dr. Mercola

Opioid-related statistics reveal the U.S. has an enormous problem on its hands. Americans use 80 percent of all the opioids sold worldwide.¹ In Alabama, which has the highest opioid prescription rate in the U.S., 143 prescriptions are written for every 100 people.² A result of this over-prescription trend is skyrocketing deaths from overdoses.^3,4

As recently reported by CNN, the Manchester, New Hampshire, fire department responds to more calls for drug overdoses than fires these days.⁵ In 2015, 52,404 Americans died from drug overdoses; 33,091 of them involved an opioid and nearly one-third of them, 15,281, were by prescription.^6,7,8

The following graph by the National Institute on Drug Abuse shows the progressive incline in overdose deaths related to opioid pain relievers between 2002 and 2015.⁹ This does not include deaths from heroin addiction, which we now know is a common side effect of getting hooked on these powerful prescription narcotics. In all, we’re looking at just over 202,600 deaths in this 13-year time frame alone.¹⁰

Meanwhile, kidney disease, listed as the ninth leading cause of death on the Center for Disease Control and Prevention’s (CDC) top 10 list, killed 48,146.¹¹ The CDC does not include drug overdoses on this list, but if you did, drug overdoses (63 percent of which are opioids), would replace kidney disease as the ninth leading cause of death as of 2015. As if that wasn’t bad enough, recent statistics reveal that in Americans under the age of 50, opioids are now the LEADING cause of death.

In a sadly ironic twist, research reveals many other nations struggle with a dire lack of pain relief for end-stage, terminal patients. As reported by The Atlantic:¹² “Some 45 percent of the 56.2 million people who died in 2015 experienced serious suffering, the authors found. That included 2.5 million children. More than 80 percent of the people were from developing regions, and the vast majority had no access to palliative care and pain relief.”

Drug Enforcement Agency Whistleblower Speaks Out

In a recent episode of 60 Minutes,¹³ whistleblower Joe Rannazzisi lays the blame for the opioid crisis squarely on the shoulders of the drug industry — especially the drug distributors — and Congress.¹⁴

It was well-known that drug distributors were sending extraordinarily large shipments of opioids — hundreds of millions of pills — to pharmacies across the U.S., and that people were dying from their misuse; yet, rather than taking steps to stop the massacre, industry lobbyists and Congress made it virtually impossible for agents at the U.S. Drug Enforcement Agency (DEA) to take any action at all.

Rannazzisi should know. He led the DEA’s Office of Diversion Control, which specifically regulates and investigates the drug industry. According to Rannazzisi, “This is an industry that’s out of control. What they want to do is do what they want to do, and not worry about what the law is. And if they don’t follow the law in drug supply, people die.” As reported by CBS News:¹⁵

“His greatest ire is reserved for the distributors — some of them multibillion dollar, Fortune 500 companies. They are the middlemen that ship the pain pills from manufacturers, like Purdue Pharma and Johnson & Johnson to drug stores all over the country. Rannazzisi accuses the distributors of fueling the opioid epidemic by turning a blind eye to pain pills being diverted to illicit use.”

Drug Distributors Acted With Full Knowledge

The three largest drug distributors — Cardinal Health, McKesson and AmerisourceBergen — control as much as 90 percent of the opioid distribution in the U.S., and according to Rannazzisi, they were most certainly aware of the fact that the suspiciously large orders they filled were killing tens of thousands of people each year. The drug makers facilitated these killings as well, by falsely testifying to their safety and low risk of addiction when used for pain.

This lie allowed hundreds of thousands of Americans to become addicted and tens of thousands die over the past two decades. As addiction rose, so did “pill mills” — so-called pain clinics that did little more than distribute narcotics. In Rannazzisi’s words, the rapid rise in opioid abuse “made the whole crack epidemic look like nothing.” The main difference was that opioids were distributed by medical professionals rather than street gangs.

Rannazzisi was in charge of prosecuting doctors and pharmacists caught pandering the drugs to addicts, yet as soon as one was taken off the street, another would take his or her place. It did nothing to quench the epidemic. So, he decided to “move up the food chain” and go after the distributors who, by law, are required to report and stop suspicious orders. Unusually large or excessively frequent orders both fit the bill of a suspicious order, and such orders were being routinely filled without ever being reported to the DEA.

Jim Geldhof, who worked at the DEA for 40 years, attests to the fact that distributors shipped thousands of suspicious orders. One of the more obvious examples include a pharmacy in Kermit, West Virginia, which ordered 9 million hydrocodone pills over the course of two years. With a population of just 392 people, no one in their right mind could possibly mistake this for anything but a drug distribution ring.

Between 2007 and 2012, more than 12 million pills were also shipped to McDowell County in West Virginia, a county with a population of 28,000 — enough for nearly 86 pills per capita per year.¹⁶ According to Geldhof, the DEA kept looking for “a good-faith effort” by drug distributors “to do the right thing,” but there was none. “Greed always trumped compliance,” he says. DEA efforts to improve compliance also came to naught. “They just flat out ignored us,” Geldhof says.

Chump Change Fines Levied

In 2008, the DEA levied a $13.2 million fine against McKesson for the filling of hundreds of suspicious orders totaling millions of pills. Cardinal Health was also fined $34 million that same year. Such fines did nothing to stem the tide, however. Earlier this year McKesson again agreed to pay a $150 million settlement for the same violation — the largest fine ever levied against a drug distributor.

The settlement also prevents McKesson from selling controlled substances from distribution centers in Colorado, Ohio, Michigan and Florida “for multiple years,” and imposes “new and enhanced compliance obligations on McKesson’s distribution system,” according to the U.S. Department of Justice.¹⁷ Still, when you consider the enormous profits made by these companies — in 2008, Cardinal Health was reporting $3.4 billion in annual revenue — even fines in the tens of millions amount to chump change.

Drug Distributors Took Aim at DEA

In all, distributors have been slapped with fines in excess of $341 million over the past seven years,¹⁸ with little effect. On the contrary, distributors started complaining to Congress saying the DEA was “treating them like a foreign drug cartel.” In 2011, Cardinal Health took aim at Rannazzisi personally. Four years later, after having his authority greatly reduced, he resigned. As reported by CBS:

“The companies’ attorneys went over his head and called his bosses at the Justice Department, who called in Rannazzisi to have him explain his tactics. ‘And it infuriated me that I was over there, trying to explain what my motives were or why I was going after these corporations?

And when I went back to the office, and I sat down with my staff, I basically said, ‘You know, I just got questioned on why we’re doing … what we’re doing … [N]ow this is war. We’re going after these people and we’re not going to stop’ …

Rannazzisi says the drug industry used [industry] money and influence to pressure top lawyers at the DEA to take a softer approach. Former DEA attorney Jonathan Novak said it divided the litigation office. He said in 2013, he noticed a sea change in the way prosecutions of big distributors were handled.

Cases his supervisors once would have easily approved, now weren’t good enough … Novak prosecuted cases brought to him by Joe Rannazzisi’s investigators. He said his caseload started to slow down dramatically … [Jonathan Novak said:] ‘These were cases where the evidence was crystal clear that there was wrongdoing going on.’ He said his bosses started to bog down the system, demanding ever more evidence.”

Several Dozen DEA Officials Have Taken Drug Industry Jobs

According to Novak, one of the primary reasons for the slowdown in cases was the exodus of DEA lawyers that took high-paying jobs working for the drug industry. At least 56 former DEA and Department of Justice officials have been hired by the drug industry since 2000.¹⁹ Once on the industry’s side, they lobbied against the DEA, arguing the agency’s cases were weak and didn’t stand a chance in court — even though they’d consistently won most of their cases so far.

In other words, these attorneys levied their insider knowledge of potential weak points against their former employer to protect the industry — all while prescription rates, addiction rates and opioid-related overdoses kept increasing. But the industry wasn’t satisfied with slowing the DEA down to a crawl. They wanted the agency off its back permanently. So, lobbyists started working on Congress to enact legislation that would effectively eliminate the DEA’s powers of enforcement.

DEA Stripped of Its Enforcement Powers

Just such a law was passed in April 2016. The Ensuring Patient Access and Effective Drug Enforcement Act severely restricts the DEA’s ability to track and charge pharmacies and wholesalers who are expanding the opioid epidemic.

As noted by Rannazzisi, if you really wanted to harm the U.S. with drugs, “the only thing I could think of that would immediately harm is to take the authority away from the investigative agency that is trying to enforce the Controlled Substances Act and the regulations implemented under the act. And that’s what this bill did.”

As a result of this legislation, the DEA no longer has the power to freeze suspicious distribution of prescription narcotics. The law also effectively prevents people at the top of the chain from being held accountable. Overall, the DEA’s ability to go after wholesale distributors peddling narcotics to pill mills is now nearly nonexistent. As noted by Novak, the Justice Department has been rendered “toothless; I don’t know how they stop this now.”

The main sponsor of the law — and a staunch advocate for the drug industry in general — was Rep. Tom Marino, R-Pa., a former county and federal prosecutor nominated by President Trump to become the next drug czar. Fortunately, this particular fox was not entrusted with the hen house. In mid-October, Marino withdrew his name from consideration.²⁰

Marino No Longer in the Running for Drug Czar

Marino’s decision came right on the heels of this joint investigation by 60 Minutes and The Washington Post — which identified Marino as a key player in getting the bill passed²¹ — and President Trump’s announcement that his administration would look into the allegations against Marino.²² As noted by Charlie Brown, president of Consumers for Dental Choice and the World Alliance for Mercury-Free Dentistry, in a private email to me:

“Now the real battle begins. More important than the fate some Congressman from rural Pennsylvania who works secretly against his own constituents is this bad law, which Congress created hence only Congress can repeal. The handcuffs must come off DEA’s power to act against heroin drug kingpins in the corporate suites wearing their three-piece suits and lab coats — and the local distributors whose names end in M.D. and DDS and MHA (Masters in Hospital Administration).

A campaign to show Congressional complicity in heroin must get to the grassroots; accountability must begin. Congress is not tough on illegal drugs, passing laws that put a pathetic drug user in prison for life; Congress is tough on drugs by cutting off the supply and putting in prison the kingpins.”

Sen. Joe Manchin, D-W.Va., told The Washington Post²³ he was “horrified” by the revelations of the investigation, saying the true intent of Marino’s bill was “camouflaged,” such that no one understood the effect it would have on the opioid epidemic. “That bill has to be retracted, has to be repealed,” Manchin said. Sen. Claire McCaskill, D-Mo., has announced she will in fact introduce legislation to repeal it. Manchin has also suggested Rannazzisi would be a good candidate to head the DEA.

It’s worth noting the bill was actually written by former director of DEA litigation and compliance practice, Linden Barber, one of the several dozen people who swapped sides to work on behalf of the drug industry. His deep understanding of the internal workings of the agency’s enforcement strategies is part of what makes the law so effective in its ability to hinder DEA action against drug companies and distributors.

President Renews Vow to Address Opioid Epidemic

Drug companies, distributors, drugstore chains and drug manufacturers also spent $102 million lobbying for the bill, claiming the DEA was impeding patients’ ability to receive “needed medication.” With statistics clearly telling a different story, it should have been easy to see through this ruse. Clearly, it was (and is) far too easy to get your hands on these pills. Yet the drug industry won, and when they win, they typically do so at the patients’ expense.

October 16, after the 60 Minutes interview aired, President Trump announced his intention to declare opioid addiction a national emergency, thereby securing much-needed funds and policy initiatives to address the burgeoning epidemic.^24,25 He had initially supported such a move back in August, and has defended accusations of foot dragging by saying it involves a lot of time-consuming work.

CVS Takes Affirmative Action

In related news, CVS Pharmacy recently announced it will limit opioid prescriptions to a seven-day supply for certain health conditions²⁶ — nearly one-third of the average supply prescribed by U.S. doctors. As of 2015, the average prescription for an opioid was 18 days’ worth.²⁷ By doing so, CVS becomes the first pharmacy chain to restrict doctors’ ability to overprescribe the drugs. CVS pharmacists will also be required to:

• Discuss the risks of addiction with patients
• Instruct patients on secure storage and proper disposal
• Use immediate-release formulations before dispensing extended-release versions, to lower the patient’s risk of building tolerance

The initiative is scheduled to roll out as of February 1, 2018. CVS is also expanding its drug disposal collection program, adding an additional 750 kiosks at pharmacies across the U.S., for a nationwide total of 1,500, and is pledging an additional $2 million donation to medication-assisted treatment programs offered by community health centers. Another previous noble action they did was to refuse to sell cigarettes in their stores.

Despite Epidemic of Opioid-Related Deaths, Doctors Are Still Being Paid to Increase Opioid Sales

Clearly, to really rein in the problem of overprescriptions and addiction, doctors need to change their prescription habits. Patients need to take greater responsibility for their own well-being as well. More than 33,000 Americans were killed by opioids in 2015, and nearly half of them involved a prescription for the drugs.

Knowing that these drugs carry the serious risk of addiction, abuse and overdose, they should be prescribed sparingly and only for the most severe cases of pain, for which no other options are available. Instead, they are often prescribed widely to treat milder cases of chronic pain, such as that from osteoarthritis or back pain, the latter of which has turned into a major “gateway condition” that traps unsuspecting patients in the grip of addiction.

Unfortunately, the current medical system heavily discourages doctors from making much-needed changes in their prescription habits. Patient pain assessment plays a significant role in a doctor’s quality of care indicator, and nothing will eliminate pain as effectively as a narcotic. In other words, if patients report not getting pain relief, a doctor’s rating will go down. On top of that, and in the midst of this epidemic of opioid overdose deaths, drug companies are also still paying physicians to boost opioid sales by writing more prescriptions.

According to a study published in the American Journal of Public Health,²⁸ between August 2013 and December 2015, more than 375,000 nonresearch opioid-related payments were made to more than 68,000 physicians, totaling in excess of $46 million. This amounts to 1 in 12 U.S. physicians collecting money from drug companies producing prescription opioids.

The top 1 percent of physicians received nearly 83 percent of the payments, and the drug fentanyl, a synthetic opioid that can be anywhere from 500 to 1,000 percent more potent than morphine, was associated with the highest payments. Many of the states struggling with the highest rates of overdose deaths, such as Indiana, Ohio and New Jersey, were also those showing the most opioid-related payments to physicians. This suggests there’s a direct link between doctors’ kick-backs and patient addiction rates and deaths.

It’s also worth noting that a significant amount of people get their first opioid prescription from their dentist.²⁹ This is particularly true for teenagers and young adults.³⁰ Half of all opioids are also prescribed to people with mental health problems.³¹

Nondrug Solutions for Pain Relief

It’s extremely important to be fully aware of the addictive potential of opioid drugs, and to seriously weigh your need for them. There are many other ways to address pain. Below is a long list of suggestions. Clearly, there are times when pain is so severe that a narcotic pain reliever may be warranted. But even in those instances, the options that follow may allow you to at least reduce the amount you take, or the frequency at which you need to take them.

If you are in pain that is tolerable, please try these options first, before resorting to prescription painkillers of any kind. If you need a pain reliever, consider an over-the-counter (OTC) option. Research³² shows prescription-strength naproxen (Naprosyn, sold OTC in lower dosages as Aleve) provides the same pain relief as more dangerous narcotic painkillers. However, while naproxen may be a better alternative to narcotic painkillers, it still comes with a very long list of potential side effects,³³ and the risks increase with frequency of use.

Source:: Mercola Health Articles